This bill allows veterans with mental health conditions transitioning from Department of Defense (DoD) to Department of Veterans Affairs (VA) care to continue seeing their current DoD mental health provider during the switch. It requires the VA to reimburse the DoD for services provided under this provision, ensures veterans can switch to another DoD provider at the same facility if their current provider leaves, and mandates that medical records be transferred to the VA upon transition. The policy directly affects veterans enrolled in or transitioning to the VA's patient system who have a diagnosed mental health condition. It creates a structured process for continuity of care during the federal health system transition, avoiding abrupt provider changes.
This bill amends Medicare eligibility rules to clarify that beneficiaries needing occupational therapy *or* speech therapy qualify for home health services. It updates two sections of the Social Security Act (Parts A and B) to replace "need occupational therapy or speech therapy" with "need occupational, or speech therapy," ensuring both therapies are explicitly covered. The change directly affects Medicare beneficiaries requiring either therapy for home-based care, removing potential confusion about eligibility. The updated rules will take effect for services provided on or after January 1, 2026.
This bill removes pay caps for therapeutic and diagnostic medical physicists employed by the Department of Veterans Affairs (VA). It directly affects VA-employed medical physicists who specialize in radiation treatment planning (therapeutic) and imaging diagnostics (diagnostic), who previously faced lower pay rates than other VA healthcare professionals. The key mechanism amends Title 38 of the U.S. Code to insert these roles into pay classifications, qualifications, and grade structures alongside physicians, podiatrists, and dentists. The bill also requires the VA Secretary to submit a report within one year assessing the impact of these pay changes on staffing, costs, and care provided under VA agreements.
This bill requires hospitals to screen all infants under 21 days old for congenital cytomegalovirus (CMV), a common viral infection that can cause hearing loss and developmental delays. It directs state health officials to establish screening standards and procedures, with the federal Advisory Committee stepping in if states fail to act within two years of the law's enactment. The bill authorizes funding through the Health Resources and Services Administration, Centers for Disease Control and Prevention, and National Institutes of Health to support state screening programs, data systems, healthcare provider training, and research on CMV screening and treatments. These provisions directly affect newborns in hospitals, healthcare providers administering tests, and state public health agencies implementing the screening requirements.
S 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, requires Medicare to cover FDA-designated "breakthrough" medical devices during a 4-year transitional period starting when the device is approved. This directly affects Medicare beneficiaries (Part A/B enrollees) and device manufacturers, ensuring coverage for these innovative products while FDA reviews their safety. The bill mandates that Medicare’s coverage decisions for these devices must be finalized within 9-12 months before the 4-year period ends, and allows coverage denial only if clinical data shows the device poses undue risk. It also allocates $10 million annually (2026-2031) to fund Medicare’s implementation of these coverage rules.
This bill creates new funding opportunities for rural health facilities (like hospitals, clinics, and long-term care centers) in areas with populations under 50,000. It allows these facilities to use existing Rural Development Agency funds to refinance debt, update telehealth/equipment, or cover operating costs - provided the assistance preserves health access and improves the facility’s financial health. Eligibility requires the facility to be in a rural area or a persistent poverty area (defined as a 20%+ poverty rate for 30 years), and the Secretary may waive certain requirements for insolvent facilities in distressed communities. The law amends existing farm and rural development programs to directly support rural health infrastructure without creating new funding streams.
HR 3762, the Supporting Healthy Moms and Babies Act, requires health insurance plans to cover comprehensive prenatal, childbirth, neonatal, perinatal, and postpartum care without cost-sharing (like copays or deductibles). It mandates specific services including ultrasounds, care for pregnancy loss, delivery support, and postpartum behavioral health services for conditions like diabetes or hypertension. The bill applies to group health plans and individual insurance policies starting after the law's enactment, covering both biological mothers and legal parents who did not give birth. This policy directly affects insured individuals seeking maternal and newborn healthcare, ensuring these essential services are fully covered under existing Affordable Care Act requirements.
HR 307, the ARC Act of 2025, aims to reduce avoidable amputations by expanding access to peripheral artery disease (PAD) screening and prevention. It requires Medicare and Medicaid to cover PAD screening tests (like ankle-brachial index tests) without cost-sharing for at-risk beneficiaries, including seniors, diabetics, and those with other vascular risk factors. The bill also establishes a federal education program to raise awareness about PAD and creates quality measures to incentivize hospitals to prioritize non-amputation treatments through early detection. These provisions directly affect millions of Americans, particularly minorities disproportionately impacted by PAD-related amputations, by making preventive care more accessible and integrated into routine care.
The ICHRA Permanency Act makes permanent a 2019 federal rule that allows employers to offer health reimbursement arrangements (HRAs) to cover individual health insurance premiums and out-of-pocket medical costs. This directly affects small employers and their employees, enabling businesses to provide tax-advantaged health coverage without requiring group plans. The bill codifies the existing rule into law, ensuring it has the full force of law and cannot be altered by future administrations. This creates a stable framework for employers using HRAs to help workers afford health coverage.
S 3019, the "No Big Blockbuster Bailouts Act," amends Medicare's drug price negotiation program to change how orphan drugs (treatments for rare diseases) are handled. It raises the revenue threshold from $200 million to $400 million before orphan drugs become subject to price negotiations under Medicare. This directly affects pharmaceutical companies developing drugs solely for rare diseases, as they will face price negotiations only if their annual U.S. revenue exceeds $400 million. The change applies to initial price negotiations starting January 1, 2028.
